Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management (NCT04567225), a non-randomized phase 4 study. The primary outcome is Time to Anion Gap Closure.

2. Clinical Question

The study focused on whether the timing of basal insulin administration could be assessed in relation to anion gap closure during diabetic ketoacidosis management. That clinical question depends on comparing time-to-event information: the event is reaching the stated anion gap threshold, and the time origin is the start of the insulin infusion. The registry record also lists hospital and ICU length of stay, total IV insulin infusion dose, transitional failure, hyperglycemia, and hypoglycemia as secondary outcomes.

The comparison requires cautious interpretation because the early-glargine cohort and the retrospective standard-practice cohort were not assigned by randomization. The registry describes the latter as matched and prespecified, but does not report the matching variables or a statistical analysis plan. Most importantly, the registry says that the study could not be completed as planned and that no data were collected for analysis. Thus, the record identifies a clinical question and planned comparison, but supplies no comparative outcome estimate.

3. Trial Design

The registry classifies this as a phase 4, nonrandomized, unmasked study with a single-group model. Its arm descriptions nevertheless identify an early-glargine group and a retrospective standard-practice group. This means the record contains a planned comparison, but not a randomized, concurrent, like-for-like control comparison. The registry does not explain the difference between its single-group classification and the two described cohorts.

The early-glargine description concerns consecutive adult patients admitted to a Medical ICU who met inclusion criteria and accepted early glargine according to the protocol. The listed dose and timing are 0.4 unit/kg within 4 hours from initiating the IV insulin infusion. The comparator is described as a retrospective, prespecified, matched sample of consecutive adults admitted to the same Medical ICU with diabetic ketoacidosis between January 1st 2019 and the Institutional Review Board approval date. The description says this group did not receive basal insulin before anion gap closure.

The registry lists enrollment as 39 and identifies The Cleveland Clinic as the sponsor. The recorded start date is 2020-10-01, and the primary completion date is 2021-08-27. The current status is terminated. The stated reason is that the study was closed because of lack of proper resource availability; the registry also says it could not be completed as planned and no data were collected for analysis.

These design features limit what the intended comparison could establish even if outcome data had been available. Nonrandom assignment can leave groups different in ways related to outcomes, and retrospective data may be collected under different circumstances from data gathered prospectively. Matching can address specified characteristics, but the matching variables and any residual adjustment strategy are not reported in the registry record. With no analysis results, the record cannot show whether the planned comparison was completed or how any potential group differences were handled.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: The study was closed due to lack of proper resource availability. Since study could not be completed as planned, no analysis was completed. This included no enrollment into the chart review arm.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Study withdrawn. The study was closed due to lack of proper resource availability. Since study could not be completed as planned, no data was collected for analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Study withdrawn. The study was closed due to lack of proper resource availability. Since study could not be completed as planned, no analysis was completed.

6. Primary Endpoint

The registry lists the primary outcome as Time to Anion Gap Closure, measured over Participants monitored from hospital admission to discharge, an average of 5 days.

The primary endpoint is time to anion gap closure. It is defined as the number of hours from starting the insulin infusion until the anion gap is 12 milliequivalent/Liter or less. The registry describes participants as monitored from hospital admission to discharge, with an average of 5 days as the timeframe.

Anion gap closure is used as a defined clinical milestone in diabetic ketoacidosis management. Measuring the elapsed time to a threshold treats the outcome as a time-to-event measure: the event is reaching the specified threshold, and the clock begins at insulin infusion initiation. In general, time-to-event outcomes can retain information about when an event occurs, rather than reducing the result to whether it occurred by a fixed time. That interpretation depends on having valid event times and appropriate analysis, neither of which is available in this record.

The registry gives no primary endpoint value, event-time summary, uncertainty interval, or statistical test. It explicitly states that the study was withdrawn and that no data were collected for analysis. The endpoint definition therefore describes the intended measurement, not an observed result. No conclusion about the timing of anion gap closure can be drawn from the endpoint entry.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What was the planned comparison?

The registry describes early glargine alongside a retrospective standard-practice cohort. The early group was intended to include consecutive adults admitted to a Medical ICU who met the inclusion criteria and accepted early glargine. The comparator was described as a prespecified, matched retrospective sample of consecutive adults admitted to the same ICU with diabetic ketoacidosis who had not received basal insulin before anion gap closure. The registry labels allocation nonrandomized and masking none. These details describe how the study was intended to be organized; they do not establish that usable comparison data were collected.

In general, random allocation helps balance measured and unmeasured prognostic characteristics across groups. A nonrandomized design does not provide that protection by design. Matching may make groups more similar for characteristics selected by investigators, but its value depends on which characteristics were matched and how the analysis treated the matched observations. Those details are not reported in the registry record. The registry's single-group model classification also sits alongside its description of a comparator; the record does not reconcile these descriptions.

What does the primary endpoint measure?

Time to anion gap closure is a time-to-event outcome. Its event is reaching an anion gap of 12 milliequivalent/Liter or less, and the stated starting point is initiation of the insulin infusion. In general, a time-to-event analysis uses both whether an event occurred and when it occurred. It may also need to account for participants whose event time is unknown or who are no longer observed before the event. The registry does not report event times, censoring information, or a completed analysis, so no such analysis can be evaluated for this trial.

The endpoint's timeframe is described as monitoring from hospital admission to discharge, with an average of 5 days. This timeframe does not substitute for an endpoint result. The record does not report a summary of observed hours to closure or an estimate comparing the planned cohorts.

What can an estimate and its uncertainty tell readers?

In general, an effect estimate summarizes the outcome contrast calculated from observed data. A confidence interval expresses the precision of that estimate under the chosen statistical model and assumptions. A wider interval generally indicates less precision than a narrower one; an interval is not a guarantee that a particular value is correct. A p-value, when reported, addresses compatibility between data and a specified null model under its assumptions. It does not measure clinical importance and does not establish the probability that a treatment works.

None of these inferential results is reported for the primary endpoint in this record. The registry states that no data were collected for analysis, and it lists zero analyses. There is no basis for explaining a trial-specific estimate, confidence interval, p-value, or model fit. General statistical definitions cannot fill that evidentiary gap.

Why does nonrandomization matter?

In general, a treatment choice may be associated with patient characteristics, care processes, or calendar time. If those factors also relate to an outcome, a crude comparison can mix differences in treatment with differences in the groups. A retrospective comparator may also differ from a prospectively assembled group in how information was recorded. Matching and adjustment can address some measured differences, but cannot guarantee removal of unmeasured confounding. The registry record does not report which variables were matched, any adjustment methods, or any diagnostics of group comparability.

The comparator's retrospective period is described as running from January 1st 2019 until the Institutional Review Board approval date. The early-glargine group is described in relation to the study protocol. Because these cohorts arise in different periods and by different selection processes, calendar and selection differences are relevant general considerations. The record supplies no analysis that can assess their impact.

What statistical plan is reported?

The registry lists seven outcome measures, but does not report an analysis plan for those outcomes. Details such as the planned model, covariate adjustment, handling of missing observations, or approach to multiple outcomes are not reported in the registry record. A sample-size justification is not reported in the registry record. General methods can explain why such choices matter, but they cannot be attributed to this trial without a registry description.

Most importantly, the stated withdrawal and lack of collected analysis data mean that the planned methods cannot be judged from posted results. The registry identifies the question, endpoint, groups, and selected outcomes, but does not provide the statistical evidence needed to estimate a treatment contrast.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists seven outcome measures: time to anion gap closure as the primary outcome, and hospital length of stay, ICU length of stay, total IV insulin infusion dose, incidence of transitional failure, incidence of hyperglycemia, and incidence of hypoglycemia as secondary outcomes. Testing or estimating multiple outcomes can raise multiplicity concerns. In general, the more outcome comparisons considered, the greater the chance that an apparently notable finding could arise by chance when many hypotheses are examined. A prespecified hierarchy or adjustment strategy can help clarify interpretation, but the registry record does not report a multiplicity plan.

The record reports zero analyses and states that no data were collected for analysis after the study was withdrawn. It therefore provides no outcome estimates to interpret, adjusted or otherwise. The statistical analysis plan, including any planned handling of missing observations, is not reported in the registry record.

Missingness cannot be characterized from the posted results. The registry does not report whether any participants had incomplete follow-up, how much outcome information was available, or whether observations were excluded from an analysis. Since it says no data were collected for analysis, there is no reported analysis population whose inclusion criteria can be assessed.

In general, missing-data methods depend on why information is missing and on the amount and pattern of missingness. Those methods cannot recover trial-specific information that was never collected or described. The stated resource-related termination is important context for the absence of analysis, but does not indicate what the unobserved outcomes would have been.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry's safety listing gives the Early Glargine group as having 39 at risk for serious adverse events, with zero affected, and 39 at risk for other adverse events, also with zero affected. It lists zero deaths for this group. The Standard Practice (Late Glargine) group is listed with zero at risk for these event categories and zero deaths.

These entries are not a comparative safety result. With zero participants at risk listed for the standard-practice group, the registry provides no comparator safety denominator. The zero event counts in the early group should be read as registry entries, not as proof that adverse events cannot occur or that the intervention is safe. A study with limited or incomplete information may not characterize uncommon events precisely.

The registry also states that the study was withdrawn because it could not be completed as planned and that no data were collected for analysis. The safety figures do not resolve that absence of a completed analysis. The record does not report event definitions, follow-up completeness, or a statistical comparison of adverse events. These entries therefore support only a narrow description of what the registry lists, not a broad conclusion about relative safety.

12. What the Result Does, and Does Not, Mean

The record documents a planned investigation of early basal insulin administration in adults admitted to a Medical ICU with diabetic ketoacidosis. It specifies a primary endpoint—time from starting IV insulin infusion to anion gap closure at 12 milliequivalent/Liter or less—and describes an early-glargine cohort and a retrospective standard-practice comparator. It also names secondary outcomes concerning hospital and ICU length of stay, IV insulin dose, transitional failure, hyperglycemia, and hypoglycemia.

However, the registry says the study was closed because of lack of proper resource availability, could not be completed as planned, and collected no data for analysis. No result is reported for the primary endpoint or secondary outcomes. There is no estimated difference, uncertainty interval, or inferential test in the record. The trial therefore does not provide a statistical answer to its stated clinical question.

This absence of results is not evidence that the approaches produced the same outcomes, nor is it evidence that either approach produced better or worse outcomes. It also does not establish a lack of adverse events. The posted safety entries show zero events in the Early Glargine group and no participants at risk listed for the standard-practice group, so they cannot support a direct safety comparison.

Even a completed nonrandomized comparison would need careful interpretation because group assignment was not random and one cohort was retrospective. General concerns include confounding and differences in how observations were collected. The registry does not report the matching variables or statistical methods that would be needed to assess these issues. The most defensible conclusion is that the record describes an intended study but contains no analyzed efficacy or comparative safety findings.

13. Why This Trial Matters Statistically

This record matters statistically because it illustrates the difference between a registered research question and an answer supported by analyzed data. The registry defines an outcome, describes intended groups, and lists additional outcomes, but states that the study was terminated before completion and that no data were collected for analysis. Registration alone does not produce an estimate of an intervention effect.

It also highlights why design labels and comparator details matter. The study is classified as nonrandomized, unmasked, and single group, while the arm descriptions include a retrospective matched comparator. Readers need these distinctions to judge what a comparison could mean. Without randomization, matching and adjustment details become especially relevant; here, the registry does not report those methods.

The record also demonstrates that an endpoint definition is not an endpoint result. A clearly specified time origin and threshold make the intended measure understandable, but they cannot replace observed event times, a summary estimate, and a measure of uncertainty. Likewise, a list of secondary outcomes does not imply that they were measured or tested.

Finally, an incomplete study requires restraint in interpreting safety counts. Zero posted events in one group do not establish no risk, and a comparator with zero listed at risk cannot support a comparative rate. The statistical lesson is not a conclusion about early glargine; it is that the registry's limited data do not permit an outcome comparison.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation is explicit in the registry: the study was withdrawn, could not be completed as planned, and collected no data for analysis. There is no reported primary endpoint result or analysis of the secondary outcomes. The record's enrollment figure does not establish how many participants contributed outcome data or whether an analysis population existed.

The design also limits what the intended comparison could establish. Allocation was nonrandomized and masking was none. The comparator was retrospective, whereas the early-glargine group was described in relation to the protocol. The registry says the comparator was matched but does not identify the matching variables or report any balance assessment. The single-group model classification is not reconciled with the description of two cohorts.

The registry does not report a statistical analysis plan, a sample-size justification, methods for missing data, or a multiplicity strategy for the listed outcomes. It also does not provide details on outcome-specific follow-up completeness or on how the retrospective records would be analyzed. These omissions prevent assessment of planned inferential choices.

The safety entries offer limited information: the standard-practice group is listed with zero at risk, and no comparative safety analysis is reported. The registry does not provide enough information to treat the zero counts as a complete or precise assessment of adverse events. These limitations are in addition to, and do not overcome, the central absence of analyzed outcome data.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management — NCT04567225.
• Registry record last updated 2022-09-21; status last verified 2022-08.
• Results first posted 2022-08-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes a phase 4, nonrandomized, unmasked study sponsored by The Cleveland Clinic, with a single-group model classification. It concerns early glargine administration for adults with diabetic ketoacidosis in a Medical ICU and describes a retrospective matched standard-practice cohort. The stated primary endpoint is time from insulin infusion initiation to anion gap closure at 12 milliequivalent/Liter or less.

The record lists enrollment as 39, a start date of 2020-10-01, a primary completion date of 2021-08-27, and status as terminated. It states that the study was closed because of lack of proper resource availability, was not completed as planned, and collected no data for analysis. No primary or secondary outcome analysis is reported. The posted record therefore describes the intended study question and design but does not provide an estimate of the clinical outcomes or a comparative treatment effect.